VEGFA and breast carcinoma: Although this agent has yet to be tested in a bone metastatic patient setting, preclinical studies using similar antibody antagonists to IL-6R were shown to inhibit breast cancer bone metastasis growth and decrease osteolysis concomitant with downregulation of expression of important factors such as VEGF and RANK in preclinical models [246].